HOME >> MEDICINE >> NEWS
New compound holds promise for lupus and related diseases

Ann Arbor, MI A chemical cousin of anti-anxiety medications, such as Valium and Xanax, significantly reduces kidney inflammation in mice inbred to develop a disease resembling human systemic lupus erythematosus (SLE), researchers at the University of Michigan and the University of California-Berkeley have found.

Their research, described in the Oct. 16 issue of the Journal of Clinical Investigation, also reveals the novel mechanism by which the compound works, a discovery that could lead to safer and more effective new drugs for managing lupus and other autoimmune disorders.

"The best available therapies for lupus haven't changed for many, many years," says U-M's Gary D. Glick, Ph.D., one of the lead authors on the study. "It's a disease where the mechanisms that normally prevent the immune system from attacking components of one's own body are defective. Because we do not yet understand what triggers lupus, it has been very difficult to develop lupus-specific therapies."

In fact, the mainstays of treating lupus-related kidney inflammation---the major cause of illness and death in lupus patients---are drugs developed many years ago to kill cancer cells. When given to lupus patients, often in combination with immune-suppressing steroids, these cytotoxic agents kill immune cells. But because they lack specificity, they also kill healthy cells, resulting in serious side effects. What's more, they simply are not effective in some patients.

"Our compound, on the other hand, goes in and kills the bad players but leaves the good players alone," says Glick, a charter faculty member of the U-M Life Sciences Institute, who is the Werner E. Bachmann Collegiate Professor of Chemistry, and a professor of biological chemistry in the U-M Medical School.

The compound, a 1,4-benzodiazepine (designated as Bz-423), sets off a chain of events that results in apoptosis, a natural cell-suicide process by which the body rids itself of cells
'"/>

Contact: Sally Pobojewski
pobo@umich.edu
734-615-6912
University of Michigan Health System
16-Oct-2002


Page: 1 2 3

Related medicine news :

1. New compounds effective against Alzheimers disease onset and progression
2. Marijuana-like compounds may aid array of debiliating conditions ranging from Parkinsons to pain
3. New compounds show promise in fighting malaria and cancer
4. Blueberry compound shows promise of lowering cholesterol as effectively as drug
5. New class of compounds promises to revive failing hearts
6. New compound may act to keep thyroid activity in check
7. Study finds certain compounds in beer, wine effective in slowing breast cancer cell growth
8. Researchers testing compounds that may stop replication of T-cell leukemia virus
9. Cocoa froths with cancer-preventing compounds
10. Alcohol may compound its damaging effects through frontocerebellar circuitry
11. Synthetic marijuana compound reduces agitation, improves appetite in Alzheimers patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... Torrance dentist, ... aesthetics can be one of the most noticeable aspects of a person’s appearance. A ... not everyone is born with beautiful, balanced teeth, everyone can have the smile of ...
(Date:6/26/2017)... ... June 26, 2017 , ... Dr. Martin ... Specialists, in collaboration with the Fertility Center of California, is pleased to announce ... epidydimal sperm aspiration) and TESA (percutaneous testicular sperm extraction). These minimally invasive treatments ...
(Date:6/26/2017)... ... June 26, 2017 , ... ... recent review of government data released by the United Soybean Board. , ... Maryland’s soybean farmers have increased their productivity on less land per bushel, the ...
(Date:6/26/2017)... ... June 26, 2017 , ... LARKR™ , an innovative ... in every state across the country to join its online treatment platform. , ... therapists to reach a substantially greater number of people in need nationwide, and to ...
(Date:6/26/2017)... ... 26, 2017 , ... KICKICO , a protocol built on Ethereum for ... many catastrophic issues within funding campaigns. KICKICO developers are testing the platform, which will ... the raising of funds through the power of many - has been around for ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)...  In 2016, Embodied Labs took top ... and came away with $25,000 in seed-fund investment. Embodied ... as "entering the life of another" and by the ... to medical professionals in an entirely new dimension." Building ... finalist for the Department of Education,s EdSimChallenge, where they ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company ... from three Phase 3 studies of galcanezumab, an investigational ... including late-breaking data on several key secondary endpoints for ... results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will ... annual scientific meeting in Boston . ...
(Date:6/9/2017)... and INDIANAPOLIS , June ... are living with diabetes. In a further effort to ... people affected by this condition, the International Diabetes Federation ... LLY ) have come together for the second phase ... and Systems programme (BRIDGES 2), reaffirming their commitment to ...
Breaking Medicine Technology:
Cached News: